Company intelligence / Profile preview

ILJIN SNT

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

ILJIN SNT is a Korean investment firm and industrial holding company, notable for its significant positions in biotech firms such as Aurinia Pharmaceuticals and for public campaigns to influence their governance; ILJIN SNT does not develop pharmaceutical or biotech products itself.

Industry: Investors

Partnerships

Aurinia Pharmaceuticals (as major minority shareholder, not as a product partnership)

Beyond the preview

Go deeper on ILJIN SNT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ILJIN SNT.

Explore the full profile